Advertisement

Abdominal Radiology

, Volume 44, Issue 10, pp 3312–3324 | Cite as

CT and MR imaging of chemotherapy-induced hepatopathy

  • Federica VernuccioEmail author
  • Marco Dioguardi Burgio
  • Filippo Barbiera
  • Silvestro Cusmà
  • Giuseppe Badalamenti
  • Massimo Midiri
  • Valérie Vilgrain
  • Giuseppe Brancatelli
Review

Abstract

Chemotherapy-induced hepatopathy includes a wide variety of parenchymal and vascular hepatic changes on imaging, including diffuse or focal hepatopathies (i.e. hepatitis, steatosis, fibrosis, pseudocirrhosis, or sinusoidal obstruction). These changes can profoundly alter the hepatic parenchyma on imaging and result in both false negative and false-positive diagnoses of hepatic metastases and lead to errors in patient management strategies. It is therefore important for radiologists to have a comprehensive knowledge of the imaging patterns that may develop following chemotherapy. The purpose of this review is to explore the broad spectrum of hepatic parenchymal and vascular chemotherapy-induced changes on CT and MR imaging.

Keywords

Chemotherapy Hepatopathy Computed tomography Magnetic resonance imaging Sinusoidal obstruction syndrome 

Notes

Compliance with ethical standards

Disclosures

FV, M.D.B., F.B., S.C., G. Badalamenti, M.M., V.V.: Nothing to disclose. G. Brancatelli: has received lecture fees from Bayer.

Supplementary material

261_2019_2193_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 17 kb)

References

  1. 1.
    Grigorian A, O’Brien CB (2014) Hepatotoxicity Secondary to Chemotherapy. J Clin Transl Hepatol 2:95–102.Google Scholar
  2. 2.
    Sharma A, Houshyar R, Bhosale P, Choi JI, Gulati R, Lall C (2014) Chemotherapy induced liver abnormalities: an imaging perspective. Clin Mol Hepatol 20:317–326.CrossRefGoogle Scholar
  3. 3.
    Ramadori G, Cameron S (2010) Effects of systemic chemotherapy on the liver. Ann Hepatol 9:133–143.CrossRefGoogle Scholar
  4. 4.
    Cohen AD, Kemeny NE (2003) An update on hepatic arterial infusion chemotherapy for colorectal cancer. Oncologist 8:553–566.CrossRefGoogle Scholar
  5. 5.
    Lewandowski RJ, Geschwind JF, Liapi E, Salem R (2011) Transcatheter intraarterial therapies: rationale and overview. Radiology 2011;259:641–657.CrossRefGoogle Scholar
  6. 6.
    Uslusoy HS, Nak SG, Gülten M, Biyikli Z (2009) Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol;15: 1863–1868.CrossRefGoogle Scholar
  7. 7.
    Oba A, Mise Y, Ito H, et al (2018) Clinical implications of disappearing colorectal liver metastases have changed in the era of hepatocyte-specific MRI and contrast-enhanced intraoperative ultrasonography. HPB (Oxford) 20:708–714.CrossRefGoogle Scholar
  8. 8.
    Iannaccone R, Federle MP, Brancatelli G, et al (2006) Peliosis hepatis: spectrum of imaging findings. Am J Roentgenol 187:W43–52.CrossRefGoogle Scholar
  9. 9.
    Furlan A, Brancatelli G, Dioguardi Burgio M, et al (2018) Focal Nodular Hyperplasia After Treatment With Oxaliplatin: A Multiinstitutional Series of Cases Diagnosed at MRI. Am J Roentgenol 210:775–779CrossRefGoogle Scholar
  10. 10.
    Han NY, Park BJ, Sung DJ, et al (2014) Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid–enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation. Radiology 271:416–425.CrossRefGoogle Scholar
  11. 11.
    Viganò L, Capussotti L, De Rosa G, et al (2013) Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg;258(5):731–740; discussion 741-2.Google Scholar
  12. 12.
    Krishna M (2017) Patterns of necrosis in liver disease. Clinical Liver Disease 10:53–56CrossRefGoogle Scholar
  13. 13.
    Jeong WK, Choi SY, Kim J (2013) Pseudocirrhosis as a complication after chemotherapy for hepatic metastasis from breast cancer. Clin Mol Hepato 19:190–194.CrossRefGoogle Scholar
  14. 14.
    Vilgrain V, Lagadec M, Ronot M (2016) Pitfalls in Liver Imaging. Radiology 278:34–51.CrossRefGoogle Scholar
  15. 15.
    Young ST, Paulson EK, Washington K, Gulliver DJ, Vredenburgh JJ, Baker ME (1994) CT of the liver in patients with metastatic breast carcinoma treated by chemotherapy: findings simulating cirrhosis. Am J Roentgenol 163:1385–1388CrossRefGoogle Scholar
  16. 16.
    Qayyum A, Lee GK, Yeh BM, Allen JN, Venook AP, Coakley FV (2007) Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Clin Imaging 31:6–10.CrossRefGoogle Scholar
  17. 17.
    Adike A, Karlin N, Menias C, Carey EJ (2016) Pseudocirrhosis: A Case Series and Literature Review. Case Rep Gastroenterol 10:381–391.CrossRefGoogle Scholar
  18. 18.
    Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK (1998) Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 77:2008–2011CrossRefGoogle Scholar
  19. 19.
    Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845–853.CrossRefGoogle Scholar
  20. 20.
    Rubbia-Brandt L, Lauwers GY, Wang H, et al (2010) Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56:430–439.CrossRefGoogle Scholar
  21. 21.
    Vauthey JN, Pawlik TM, Ribero D, et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065–2072CrossRefGoogle Scholar
  22. 22.
    Robinson SM, Wilson CH, Burt AD, Manas DM, White SA (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19:4287–4299.CrossRefGoogle Scholar
  23. 23.
    Bethke A, Kühne K, Platzek I, Stroszczynski C (2011) Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography. Cancer Imaging 11:91–99CrossRefGoogle Scholar
  24. 24.
    Berger-Kulemann V, Schima W, Baroud S, et al (2012) Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. Eur J Surg Oncol 38:670–676CrossRefGoogle Scholar
  25. 25.
    Tang A, Desai A, Hamilton G, et al (2015) Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 274:416–425.CrossRefGoogle Scholar
  26. 26.
    Idilman IS, Aniktar H, Idilman R, et al (2013) Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. Radiology 267:767–775CrossRefGoogle Scholar
  27. 27.
    Reissfelder C, Brand K, Sobiegalla J, et al (2014) Chemotherapy-associated liver injury and its influence on outcome after resection of colorectal liver metastases. Surgery 155:245–254.CrossRefGoogle Scholar
  28. 28.
    Zhao J, van Mierlo KMC, Gómez-Ramírez J, et al (2017) Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg 104:990–1002.CrossRefGoogle Scholar
  29. 29.
    Vauthey JN, Mizuno T, Overman MJ, Soubrane O (2017) Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside? J Hepatol 67:10–11CrossRefGoogle Scholar
  30. 30.
    Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S (2018) Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Nat Rev Gastroenterol Hepatol 15:461–478.CrossRefGoogle Scholar
  31. 31.
    Venkatesh SK, Yin M, Ehman RL (2013) Magnetic resonance elastography of liver: clinical applications. J Comput Assist Tomogr 37:887–896.CrossRefGoogle Scholar
  32. 32.
    Han NY, Park BJ, Kim MJ, Sung DJ, Cho SB (2015) Hepatic Parenchymal Heterogeneity on Contrast-enhanced CT Scans Following Oxaliplatin-based Chemotherapy: Natural History and Association with Clinical Evidence of Sinusoidal Obstruction Syndrome. Radiology 276:766–774.CrossRefGoogle Scholar
  33. 33.
    Fan CQ, Crawford JM (2014) Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol 4:332–346.CrossRefGoogle Scholar
  34. 34.
    Marzano C, Cazals-Hatem D, Rautou PE, Valla DC (2015) The significance of nonobstructive sinusoidal dilatation of the liver: Impaired portal perfusion or inflammatory reaction syndrome. Hepatology 62:956–963.CrossRefGoogle Scholar
  35. 35.
    Rubbia-Brandt L, Audard V, Sartoretti P, et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460–466CrossRefGoogle Scholar
  36. 36.
    Nakano H, Oussoultzoglou E, Rosso E, et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118–124CrossRefGoogle Scholar
  37. 37.
    Narita M, Oussoultzoglou E, Bachellier P, Jaeck D, Uemoto S (2015) Post-hepatectomy liver failure in patients with colorectal liver metastases. Surg Today 45: 1218–1226.CrossRefGoogle Scholar
  38. 38.
    Hubert C, Sempoux C, Humblet Y, et al (2013) Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab. HPB (Oxford) 15:858–864.CrossRefGoogle Scholar
  39. 39.
    Soubrane O, Brouquet A, Zalinski S, et al (2010) Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 251:454–460CrossRefGoogle Scholar
  40. 40.
    Pereyra D, Rumpf B, Ammann M, et al (2019) The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy Ann Surg Oncol 26:791–799CrossRefGoogle Scholar
  41. 41.
    Overman MJ, Ferrarotto R, Raghav K, et al (2018) The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. J Natl Cancer Inst 110:888–894.CrossRefGoogle Scholar
  42. 42.
    Hubert C, Lucidi V, Weerts J, et al (2018) Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases. Eur J Surg Oncol 44:1532–1538CrossRefGoogle Scholar
  43. 43.
    Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F, White SA, Mann DA (2013) Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol 59:318–326.CrossRefGoogle Scholar
  44. 44.
    Brancatelli G, Furlan A, Calandra A, Dioguardi Burgio M (2018) Hepatic sinusoidal dilatation. Abdom Radiol (NY) 43:2011–2022.CrossRefGoogle Scholar
  45. 45.
    Furlan A, Minervini MI, Borhani AA, Dioguardi Burgio M, Tublin ME, Brancatelli G (2016) Hepatic Sinusoidal Dilatation: A Review of Causes With Imaging-Pathologic Correlation. Semin Ultrasound CT MR 37:525–532.CrossRefGoogle Scholar
  46. 46.
    Shin NY, Kim MJ, Lim JS, et al (2012) Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 22:864–871.CrossRefGoogle Scholar
  47. 47.
    Cayet S, Pasco J, Dujardin F, et al (2017) Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation. Eur J Radiol 94:180–190.CrossRefGoogle Scholar
  48. 48.
    Yoneda N, Matsui O, Ikeno H, et al (2015) Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome. Abdom Imaging 40:3099–3103.CrossRefGoogle Scholar
  49. 49.
    Xiong WJ, Hu LJ, Jian YC, et al (2012) Focal peliosis hepatis in a colon cancer patient resembling metastatic liver tumor. World J Gastroenterol 18:5999–6002.CrossRefGoogle Scholar
  50. 50.
    Donato H, Andrade L, Bastati N, Cipriano A, Ba-Ssalamah A, Caseiro-Alves F (2018) Liver Multiacinar Regenerative Nodules: Imaging Findings and Clinical Implications. Acta Med Port 31:470–477.CrossRefGoogle Scholar
  51. 51.
    Wicherts DA, de Haas RJ, Sebagh M, et al (2011) Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol 18:659–669.CrossRefGoogle Scholar
  52. 52.
    Morris-Stiff G, White AD, Gomez D, et al (2014) Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases. Eur J Surg Oncol 40:1016–1020.CrossRefGoogle Scholar
  53. 53.
    Viganò L, Rubbia-Brandt L, De Rosa G, et al (2015) Nodular Regenerative Hyperplasia in Patients Undergoing Liver Resection for Colorectal Metastases After Chemotherapy: Risk Factors, Preoperative Assessment and Clinical Impact. Ann Surg Oncol 22:4149–4157.CrossRefGoogle Scholar
  54. 54.
    Vigano L, De Rosa G, Toso C, et al (2017) Reversibility of chemotherapy-related liver injury. J Hepatol 2017; 67:84–91.CrossRefGoogle Scholar
  55. 55.
    Calderaro J, Azoulay D, Zafrani ES (2014) Hepatocellular carcinoma and nodular regenerative hyperplasia after chemotherapy for metastatic colorectal carcinoma. Hepatology 60:1440–1441.CrossRefGoogle Scholar
  56. 56.
    Ames JT, Federle MP, Chopra K (2009) Distinguishing clinical and imaging features of nodular regenerative hyperplasia and large regenerative nodules of the liver. Clin Radiol 64:1190–1195.CrossRefGoogle Scholar
  57. 57.
    Brisse H, Servois V, Bouche B, et al Hepatic regenerating nodules: a mimic of recurrent cancer in children. Pediatr Radiol. 2000;30(6):386–93CrossRefGoogle Scholar
  58. 58.
    Donadon M, Di Tommaso L, Roncalli M, Torzilli G (2013) Multiple focal nodular hyperplasias induced by oxaliplatin-based chemotherapy. World J Hepatol 5:340–344CrossRefGoogle Scholar
  59. 59.
    Yoneda N, Matsui O, Kitao A, et al (2016) Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background. Radiographics 36:2010–2027CrossRefGoogle Scholar
  60. 60.
    Morana G, Grazioli L, Kirchin MA, et al (2011) Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 46:225–239CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Federica Vernuccio
    • 1
    • 2
    • 3
    Email author
  • Marco Dioguardi Burgio
    • 3
    • 4
  • Filippo Barbiera
    • 5
  • Silvestro Cusmà
    • 6
  • Giuseppe Badalamenti
    • 7
  • Massimo Midiri
    • 8
  • Valérie Vilgrain
    • 3
    • 4
  • Giuseppe Brancatelli
    • 8
  1. 1.Dipartimento Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”University Hospital “Paolo Giaccone”, University of PalermoPalermoItaly
  2. 2.I.R.C.C.S. Centro Neurolesi Bonino Pulejo, Contrada Casazza, SS113MessinaItaly
  3. 3.Hôpitaux Universitaires Beaujon, RadiologyClichyFrance
  4. 4.Laboratory of Imaging Biomarkers, Center of Research on Inflammation, UMR 1149, INSERMUniversity Paris-DiderotParisFrance
  5. 5.Azienda Sanitaria Provinciale Agrigento - UO Complessa Radiologia Distretto Ag 2 Sciacca-Ribera. Presidio Ospedaliero di Sciacca (AG)Sciacca, ‎AgrigentoItaly
  6. 6.Oncologic Department“La Maddalena”PalermoItaly
  7. 7.Dipartimento di Discipline Chirurgiche, Oncologiche e Stomatologiche (Di.Chir.On.S.)University Hospital “Paolo Giaccone”PalermoItaly
  8. 8.Dipartimento di Biomedicina, Neuroscienze e Diagnostica avanzata (BIND)University of PalermoPalermoItaly

Personalised recommendations